Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US6074642A · kind A · utility
87Cited by
5References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 2, 1994 |
| Grant date | Jun 13, 2000 |
| Priority date | — |
| Expiry date | May 2, 2014 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07K2319/00
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
The use of anti-C5 antibodies, e.g., monoclonal antibodies, to treat glomerulonephritis (GN) is disclosed. The administration of such antibodies at low dosage levels has been found to significantly reduce glomerular inflammation/enlargement and other pathologic conditions associated with GN.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.